NASDAQ:CABA
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. reported net income of −$167.9M in fiscal 2025. Free cash flow was −$132.3M.Summary generated from Cabaletta Bio, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−127.0%
Debt / equityn/a
Free cash flow−$132.3M
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −46 | −54 | −75 | −125 | −172 |
| Net income | −46 | −53 | −68 | −116 | −168 |
| Free cash flow | −35 | −49 | −54 | −90 | −132 |
Recent filings
- 8-KOther events
Sep 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KAmendment to articles or bylaws
Jun 11, 2026 - 4Insider transaction report
Jun 10, 2026 - 4Insider transaction report
Jun 10, 2026 - 8-KRegulation FD disclosure
Jun 3, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026